Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Back to dashboard
Company Information
About this company
Key people
Sammy Dorf
Chairman of the Board
David Allan White
Chief Executive Officer
Karina M. Fedasz
Interim Chief Financial Officer
Joshua A. Epstein
Director
Simon Tarsh
Independent Director
Click to see more
Key facts
- Shares in issue5.89m
- EPICONCO
- ISINUS68237Q5009
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capGBX 0.00
- Employees2
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.